tmem192 Antibody

What is TMEM192 and what is its cellular localization?

TMEM192 (Transmembrane protein 192) is a lysosomal membrane protein with a molecular weight of approximately 30.9 kilodaltons. It comprises four transmembrane segments with both N- and C-termini facing the cytosol . Human TMEM192 consists of 271 amino acids, while the murine ortholog contains 266 amino acids, sharing 78% sequence identity .

What applications are TMEM192 antibodies suitable for?

TMEM192 antibodies have been validated for multiple research applications as detailed in the following table:

When selecting applications, researchers should verify each antibody's validation status for their specific experimental system as performance may vary between suppliers and clones.

What species reactivity do commonly available TMEM192 antibodies demonstrate?

Commercial TMEM192 antibodies exhibit varying cross-reactivity profiles across species:

It's critical to note that species cross-reactivity requires experimental validation. For instance, antibodies developed against human TMEM192 may not recognize murine TMEM192 despite 78% sequence identity, necessitating species-specific antibodies for certain applications .

How can researchers validate TMEM192 antibody specificity?

Validating antibody specificity is critical for ensuring reliable experimental results. For TMEM192 antibodies, several approaches have proven effective:

• Knockout/knockdown validation: This represents the gold standard for antibody validation. TMEM192-deficient (TMEM192^-/-^) mice or cells provide ideal negative controls. Western blot analysis should show absence of the specific TMEM192 band (approximately 35 kDa) in knockout samples .

• Epitope mapping: Understanding the epitope recognized by the antibody is valuable. For example, TMEM192AB1 recognizes C-terminal residues between 235-250, while TMEM192AB2 recognizes residues between 200-235 . This information helps predict cross-reactivity and interpret results.

• Overexpression systems: Transient expression of TMEM192 in cell lines provides positive controls for antibody validation. Comparing antibody reactivity between transfected and non-transfected cells helps confirm specificity .

• Fragment detection: A specific TMEM192 antibody should detect both the full-length protein (~35 kDa) and, in some cases, the N-terminal fragment (~17 kDa) derived from proteolytic processing in lysosomes .

• Cross-species reactivity testing: If working with multiple species, validation should include testing against TMEM192 from each relevant species, as antibodies may show species specificity despite sequence homology .

What expression pattern does TMEM192 exhibit across tissues?

TMEM192 shows differential expression across mammalian tissues, which has implications for experimental design and interpretation:

Researchers should consider these tissue-specific expression levels when designing experiments, particularly for immunohistochemistry or when isolating lysosomes from specific tissues. The ratio of full-length protein to the N-terminal fragment also varies across tissues, potentially indicating tissue-specific differences in proteolytic processing .

How does TMEM192 protein structure affect antibody selection?

TMEM192's structure has several features that impact antibody selection and experimental design:

• Transmembrane topology: TMEM192 contains four transmembrane domains with both N- and C-termini facing the cytosol . Antibodies recognizing cytosolic domains are accessible in permeabilized cell preparations but not in intact cells or organelles.

• Potential glycosylation: Murine TMEM192 exhibits two NxS/T (N^76^PT, N^85^YT) consensus sites, though only the second site appears to be used for N-glycosylation due to proline in the first site . This modification may affect antibody recognition.

• Homodimer formation: TMEM192 can form homodimers interconnected by disulfide bridges . Under non-reducing conditions, antibodies may detect higher molecular weight complexes.

• Proteolytic processing: TMEM192 undergoes lysosomal proteolytic processing, generating an N-terminal fragment (NTF) of approximately 17 kDa . Antibodies directed against the N-terminus will detect both full-length protein and this fragment, while C-terminal antibodies will only detect the full-length form.

• Epitope accessibility: The specific epitope recognized by different antibodies affects their utility in applications like immunoprecipitation. For instance, TMEM192AB1, which recognizes C-terminal residues (235-250), demonstrates superior performance in lysosome immunoprecipitation compared to TMEM192AB2, which targets residues 200-235 .

How can TMEM192 antibodies be used to isolate and analyze lysosomal content?

TMEM192 antibodies have revolutionized lysosomal research through immunoprecipitation-based isolation techniques:

• Tagless LysoIP method: This advanced technique utilizes antibodies against endogenous TMEM192 to immunoprecipitate intact lysosomes without requiring genetic modification of cells . The procedure involves:

  a. Cell or tissue homogenization in isotonic potassium phosphate-buffered saline (KPBS) with protease and phosphatase inhibitors

  b. Magnetic bead coupling with specific TMEM192 antibodies (TMEM192AB1 has shown superior performance)

  c. Immunoprecipitation of lysosomes from homogenates

  d. Downstream analysis of lysosomal contents using proteomics, lipidomics, or enzymatic assays

• Comparative analysis: The method allows for:

  a. Enrichment of lysosomal proteins (e.g., LAMP1, LAMTOR1, TMEM55B, CTSC, CTSD, GBA1)

  b. Analysis of disease-specific alterations in lysosomal composition

  c. Biomarker discovery in clinical samples from patients with lysosomal disorders

This approach represents a significant advance over traditional subcellular fractionation methods, providing higher purity of isolated lysosomes and compatibility with limited clinical samples .

What methodological approaches can detect TMEM192 proteolytic fragments?

The detection of TMEM192 proteolytic fragments requires specialized methodological considerations:

• Antibody selection: Antibodies recognizing the N-terminal domain of TMEM192 are essential for detecting the 17 kDa N-terminal fragment (NTF) . C-terminal antibodies will only detect the full-length protein.

• Electrophoretic conditions:

  a. Use 12-15% polyacrylamide gels to achieve optimal separation of the 17 kDa fragment from full-length protein (~35 kDa)

  b. Include appropriate molecular weight markers in the 10-20 kDa range

• Sample preparation:

  a. Minimize ex vivo proteolysis by rapid sample processing with protease inhibitors

  b. Compare reducing and non-reducing conditions, as disulfide bonds may affect migration patterns

• Experimental interventions to study proteolytic processing:

  a. Lysosomal acidification inhibitors (Bafilomycin A1, NH₄Cl) can block TMEM192 processing

  b. Brefeldin A prevents post-ER trafficking and thus delivery to lysosomes of newly synthesized TMEM192

  c. Protease inhibitors targeting various classes (serine, cysteine, aspartyl, metalloproteases) have varying effects on fragment generation

• Quantitative analysis: Densitometric analysis can determine the ratio of full-length protein to NTF across different tissues or experimental conditions .

How can TMEM192 antibodies contribute to lysosomal disease research?

TMEM192 antibodies offer powerful tools for investigating lysosomal storage disorders and other diseases involving lysosomal dysfunction:

• Biomarker identification: The tagless LysoIP method can isolate lysosomes from patient samples to identify disease-specific alterations in lysosomal content. For example, this approach has identified increased lysosomal BMP (bis(monoacylglycero)phosphate) levels in fibroblasts from patients with lysosomal storage disorders .

• Disease mechanism investigation: By enabling detailed analysis of lysosomal composition, TMEM192-based methods provide insights into pathological mechanisms. This includes:

  a. Changes in lysosomal enzyme activities

  b. Alterations in lysosomal membrane protein expression

  c. Accumulation of specific substrates in disease states

• Therapeutic monitoring: The ability to isolate lysosomes from clinical samples enables:

  a. Assessment of therapeutic efficacy in correcting lysosomal abnormalities

  b. Monitoring of disease progression through longitudinal sampling

  c. Evaluation of novel therapeutic approaches targeting lysosomal function

• Model system validation: TMEM192 antibodies can help validate disease models by comparing lysosomal alterations in patient-derived samples with those in experimental models, including iPSC-derived neurons .

What are the key experimental variables affecting TMEM192 antibody performance?

Several critical experimental variables influence TMEM192 antibody performance that researchers should optimize:

• Buffer composition:

  a. For Western blotting, RIPA buffer with appropriate protease inhibitors is typically effective

  b. For lysosome immunoprecipitation, isotonic buffers (e.g., KPBS) are critical to preserve lysosomal integrity

• Fixation conditions:

  a. For immunofluorescence, 4% paraformaldehyde fixation followed by permeabilization with 0.1-0.5% Triton X-100 typically preserves TMEM192 epitopes

  b. For immunohistochemistry, epitope retrieval methods should be empirically determined

• Antibody concentration:

  a. Working dilutions vary by application and specific antibody

  b. Titration experiments are recommended to determine optimal concentrations

• Incubation conditions:

  a. Primary antibody incubations at 4°C overnight often yield optimal results

  b. For lysosome immunoprecipitation, incubation time and temperature affect yield and purity

• Detection systems:

  a. For fluorescence applications, directly conjugated antibodies (Alexa Fluor conjugates) may provide superior signal-to-noise ratios

  b. For Western blotting, HRP-conjugated secondary antibodies with enhanced chemiluminescence detection are commonly effective

Systematic optimization of these variables is essential for achieving reliable, reproducible results across different experimental systems.

What strategies can resolve weak or absent signals in TMEM192 detection?

When encountering weak or absent signals in TMEM192 detection, researchers should consider these methodological approaches:

• Sample preparation optimization:

  a. Ensure complete lysis with appropriate detergents (e.g., 1% Triton X-100, RIPA buffer)

  b. Include fresh protease inhibitors to prevent degradation

  c. Avoid freeze-thaw cycles of samples

• Antibody selection considerations:

  a. Verify species cross-reactivity (human vs. murine TMEM192 are only 78% identical)

  b. Select antibodies recognizing appropriate epitopes (N-terminal vs. C-terminal)

  c. Consider alternative clones if one performs poorly (e.g., TMEM192AB1 vs. TMEM192AB2)

• Signal enhancement approaches:

  a. Increase sample loading for Western blotting

  b. Extend primary antibody incubation (overnight at 4°C)

  c. Use signal amplification systems (e.g., biotin-streptavidin)

  d. Consider more sensitive detection reagents

• Positive controls:

  a. Include lysates from cells overexpressing TMEM192

  b. Use tissues known to express high levels (bone marrow, thymus, spleen, kidney, brain)

How can researchers distinguish between specific and non-specific bands in TMEM192 Western blots?

Distinguishing specific TMEM192 signals from non-specific bands requires systematic validation:

• Expected banding pattern:

  a. Full-length TMEM192: ~35 kDa

  b. N-terminal fragment: ~17 kDa (tissue-dependent abundance)

  c. Additional weak band at ~20 kDa in certain tissues (bone marrow, thymus)

• Critical controls:

  a. TMEM192 knockout (TMEM192^-/-^) tissues or cells provide definitive negative controls

  b. Overexpression systems serve as positive controls

  c. Peptide competition assays can confirm epitope specificity

• Cross-validation approaches:

  a. Compare results with multiple antibody clones recognizing different epitopes

  b. Verify protein identity using immunoprecipitation followed by mass spectrometry

  c. Correlate with mRNA expression data from the same samples

• Experimental manipulations:

  a. Treatment with glycosidases can confirm glycosylated forms

  b. Lysosomal inhibitors (Bafilomycin A1, NH₄Cl) alter processing patterns

  c. Brefeldin A treatment prevents lysosomal delivery and alters fragment patterns

What experimental design considerations are important for studying TMEM192 in autophagy research?

When investigating TMEM192 in relation to autophagy, researchers should incorporate these experimental design elements:

• Autophagy flux assessment:

  a. Monitor LC3-II/I ratios under basal and stimulated conditions

  b. Track p62/SQSTM1 levels as indicators of autophagic degradation

  c. Use lysosomal inhibitors (Bafilomycin A1) to block degradation and assess flux

• Starvation experiments:

  a. EBSS medium induces autophagy and can be used to assess TMEM192 role

  b. Time-course experiments (1, 2, and 4 hours) capture dynamic changes

  c. Compare wild-type and TMEM192-deficient cells to identify specific effects

• Lysosomal function assessment:

  a. Measure lysosomal enzyme activities in isolated fractions

  b. Assess lysosomal acidification with pH-sensitive dyes

  c. Evaluate lysosomal membrane integrity and potential leakage

• Protein-protein interaction studies:

  a. Investigate TMEM192 interactions with autophagy machinery

  b. Consider proximity labeling approaches (BioID, APEX) to identify neighboring proteins

  c. Assess co-localization with autophagy markers by immunofluorescence

These approaches help establish whether TMEM192 impacts autophagy directly or indirectly through its role in lysosomal function and homeostasis.

How might TMEM192 antibodies advance biomarker discovery in lysosomal disorders?

TMEM192 antibody-based techniques offer promising avenues for biomarker discovery:

• Clinical sample applications:

  a. The tagless LysoIP method enables analysis of patient-derived samples without genetic modification

  b. This allows direct comparison between healthy controls and patients with suspected lysosomal disorders

  c. Serial sampling can track disease progression or treatment response

• Multi-omics integration:

  a. Combining proteomics, lipidomics, and metabolomics analyses of isolated lysosomes

  b. Correlation of lysosomal alterations with clinical phenotypes

  c. Identification of disease-specific signatures across multiple molecular classes

• Disease subtyping:

  a. Different mutations in the same gene may produce distinct lysosomal alterations

  b. TMEM192-based isolation can help categorize patients based on molecular phenotypes

  c. This may guide personalized therapeutic approaches

• Therapeutic monitoring:

  a. Assessing normalization of lysosomal composition following intervention

  b. Identifying persistent abnormalities despite clinical improvement

  c. Developing companion diagnostics for lysosomal-targeted therapies

What methodological innovations might enhance TMEM192 antibody applications?

Several methodological innovations could further advance TMEM192 antibody applications:

• Enhanced antibody engineering:

  a. Development of recombinant antibody fragments with improved penetration into organelles

  b. Creation of antibodies specifically targeting disease-associated conformations

  c. Generation of bispecific antibodies to simultaneously target TMEM192 and other lysosomal markers

• Microfluidic adaptations:

  a. Miniaturization of the LysoIP procedure for limited clinical samples

  b. Integration with downstream analysis platforms for rapid processing

  c. Single-cell adaptations to study lysosomal heterogeneity

• In vivo applications:

  a. Development of imaging agents based on TMEM192 antibodies

  b. Non-invasive monitoring of lysosomal dysfunction in disease models

  c. Targeted delivery of therapeutic agents to lysosomes using TMEM192 antibody conjugates

• Computational biology integration:

  a. Machine learning approaches to identify patterns in lysosomal composition data

  b. Predictive modeling of disease progression based on lysosomal alterations

  c. Systems biology integration of lysosomal function with other cellular pathways

These innovations could expand the utility of TMEM192 antibodies beyond current research applications into clinical diagnostics and therapeutic development.